45
Participants
Start Date
December 10, 2021
Primary Completion Date
November 30, 2023
Study Completion Date
November 30, 2023
RXC004
RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
RXC004
RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.
RXC004
RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.
Denosumab
Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic
pembrolizumab
Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
Wollongong Hospital, Wollongong
The Alfred Hospital - Alfred Health, Melbourne
Cambridge University Hospital NHS Foundation Trust, Cambridge
Beatson West of Scotland Cancer Care, Glasgow
St James University Hospital, Leeds
Barts Cancer Institute - Haemato-Oncology, London
University College Hospitals NHS Foundation Trust, London
Royal Free London Foundation NHS Trust, London
Imperial College Healthcare NHS Trust - Hammersmith Hospital, London
The Christie NHS Foundation Trust - Medical Oncology, Manchester
Oxford Cancer and Haematology Centre Churchill Hospital, Oxford
Weston Park Hospital, Sheffield
The Royal Marsden Hospital (Surrey), Sutton
Merck Sharp & Dohme LLC
INDUSTRY
Redx Pharma Ltd
INDUSTRY